NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Takeda Pharmaceutical Company Limited TAK
9 fiscal years on record · JPY · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
¥4.6T
▲ 7.5% vs FY2023
EPS · FY24
¥67.23
Dividend / sh · FY24
—
Payout · FY24
280%
ROE · FY24
1.5%
Net margin · FY24
2.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
JPY 4.58T
Revenue, FY2024 · full 9-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
JPY 67.23
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
1.5%
Return on equity, FY2024
ROE
Operating margin7.5%
Net margin2.4%
Return on assets0.7%
Each JPY of equity produced 2 cents of profit this year.
Returned to shareholders
JPY 318.2B
returned in FY2024 · dividends + net buybacks
Dividends paidJPY 302.5B
Net buybacksJPY 15.7B
Share of profit294.8%
Consecutive raises—
JPY 302.5B in dividends and JPY 15.7B in buybacks — 295% of the year's profit, so the payout drew on cash built up earlier.
Growth
+6.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.7%
+6.8%
Net income
−22.3%
+19.5%
EPS, diluted
−22.8%
+18.9%
Returned to shareholders
−2.1%
+2.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
1.59B
Shares outstanding, FY2024
Change, 5 years+0.9%
Change, 10 years—
The share count grew 1% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
JPY 14.25T
total assets, end of FY2024
Total assetsJPY 14.25T
EquityJPY 6.94T
CashJPY 385.1B
Gross debtJPY 4.52T
Net debtJPY 4.13T
Current ratio1.01×
Net debt stands at 60% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · JPY
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue ¥B
4581.6
4263.8
4027.5
3569.0
3197.8
3291.2
2097.2
1770.5
1732.1
Operating income ¥B
342.6
214.1
490.5
460.8
509.3
100.4
237.7
241.8
155.9
EBITDA ¥B
1104.0
942.1
1154.9
1044.0
1068.9
684.1
485.4
423.9
327.3
Income tax ¥B
66.9
−91.4
58.1
72.4
−9.9
−105.0
−7.5
30.5
27.8
Net income ¥B
107.9
144.1
317.0
230.1
376.0
44.2
135.2
186.9
114.9
EPS, diluted ¥
67.23
91.16
201.94
145.87
238.96
28.25
139.82
237.56
146.26
Dividend / sh ¥
·
·
·
·
·
·
·
·
·
Payout %
280
199
88
123
75
639
106
76
123
ROE %
1.5
2.1
5.3
4.2
7.6
0.9
3.8
9.4
·
Shares out B
1.59
1.58
1.58
1.58
1.58
1.58
1.57
0.79
0.79
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed